SCHEMBL25255083

SCHEMBL25255083

CC(C)(C)[S@@+]([O-])NC(CCOc1ccccc1)B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.34
LAP3 P28838 1/20 0.34
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
HTR1B P28222 2/20 0.33
SIGMAR1 Q99720 1/20 0.33
HTR1D P28221 1/20 0.33
ALDH1A1 P00352 1/20 0.32
RECQL P46063 1/20 0.32
KCNA3 P22001 1/20 0.31
CYP2D6 P10635 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
CASP3 P42574 1/20 0.30
RAB9A P51151 1/20 0.30
SENP7 Q9BQF6 1/20 0.30
DRD2 P14416 1/20 0.30
DRD4 P21917 1/20 0.30
DRD3 P35462 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25255086 1.00 ANPEP (0.34) ANPEPLAP3F2PRSS1HTR1B
SCHEMBL25255081 1.00 ANPEP (0.34) ANPEPLAP3F2PRSS1HTR1B
SCHEMBL20401416 0.82 ANPEP (0.42) ANPEPLAP3F2PRSS1CYP2D6
SCHEMBL20401414 0.82 ANPEP (0.42) ANPEPLAP3F2PRSS1CYP2D6
SCHEMBL20401419 0.82 ANPEP (0.42) ANPEPLAP3F2PRSS1CYP2D6
SCHEMBL25268853 0.81 GPR84 (0.34)
SCHEMBL25221969 0.81 GPR84 (0.34)
SCHEMBL25268852 0.81 GPR84 (0.34)
SCHEMBL25273102 0.81 GPR84 (0.34)
SCHEMBL25220532 0.81 GPR84 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
WO-2023107487-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 ANPEP 3603/4885LAP3 2776/4885F2 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.